SSG
ITOS

Summit Securities Group’s iTeos Therapeutics ITOS Stock Holding History

Summit Securities Group’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-81
Closed -$484 – 1252
2025
Q1 		$484 Buy
+81
New +$595 ﹤0.01% 724

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Summit Securities Group's ITOS Position: Q2 2025 in Review

Summit Securities Group sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 81 shares — an estimated $484 sold.

Summit Securities Group first reported a position in ITOS in Q1 2025 and held it in 1 quarter. The position peaked at $484 in Q1 2025. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Summit Securities Group reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 81 iTeos Therapeutics shares in Q2 2025, an estimated $484.
  • Summit Securities Group first reported a position in iTeos Therapeutics in Q1 2025 and held it in 1 quarter.
  • Summit Securities Group's iTeos Therapeutics position peaked at $484 in Q1 2025.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.